Abituzumab

Abituzumab is a humanized monoclonal antibody (mAb) targeted at CD51 (an integrin).

It is intended to inhibit αv integrins expressed on CRPC cells, tumor vessels, and osteoclasts involved in bone metastasis.[1]

It is in phase II clinical trials for metastatic castration-resistant prostate cancer (CRPC) with evidence of lower incidence of bone lesion progression.[2]

References

  1. ↑ Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts) with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC).
  2. ↑ Abituzumab Improves Bone Lesion Progression, not PFS in CRPC. Feb 2016

Further reading

This article is issued from Wikipedia - version of the Saturday, February 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.